<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" ID="P0b002ee18032dbc2">
    <name type="corporate">
         <namePart>United States Government Publishing Office</namePart>
         <role>
              <roleTerm authority="marcrelator" type="text">publisher</roleTerm>
              <roleTerm authority="marcrelator" type="code">pbl</roleTerm>
        </role>
         <role>
              <roleTerm authority="marcrelator" type="text">distributor</roleTerm>
              <roleTerm authority="marcrelator" type="code">dst</roleTerm>
        </role>
    </name>
    <name type="corporate">
         <namePart>United States</namePart>
         <namePart>Congress</namePart>
         <namePart>House of Representatives</namePart>
         <role>
              <roleTerm authority="marcrelator" type="text">author</roleTerm>
              <roleTerm authority="marcrelator" type="code">aut</roleTerm>
        </role>
         <description>Government Organization</description>
    </name>
    <typeOfResource>text</typeOfResource>
    <genre authority="marcgt">government publication</genre>
    <language>
         <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
    </language>
    <extension>
         <collectionCode>CRPT</collectionCode>
         <category>Congressional Committee Materials</category>
         <waisDatabaseName>106_cong_reports</waisDatabaseName>
         <branch>legislative</branch>
         <dateIngested>2010-08-09</dateIngested>
    </extension>
    <titleInfo>
         <title>HILLORY J. FARIAS DATE-RAPE PREVENTION DRUG ACT OF 1999</title>
    </titleInfo>
    <originInfo>
         <publisher>U.S. Government Printing Office</publisher>
         <dateIssued encoding="w3cdtf">1999-09-27</dateIssued>
         <issuance>monographic</issuance>
    </originInfo>
    <physicalDescription>
         <note type="source content type">deposited</note>
         <digitalOrigin>born digital</digitalOrigin>
         <extent>21 digital object pages</extent>
    </physicalDescription>
    <classification authority="sudocs">Y 1.1/8:</classification>
    <identifier type="uri">https://www.govinfo.gov/app/details/CRPT-106hrpt340</identifier>
    <identifier type="local">P0b002ee18032dbc2</identifier>
    <identifier type="former package identifier">f:hr340p1.106.txt</identifier>
    <recordInfo>
         <recordContentSource authority="marcorg">DGPO</recordContentSource>
         <recordCreationDate encoding="w3cdtf">2010-08-09</recordCreationDate>
         <recordChangeDate encoding="w3cdtf">2024-11-10</recordChangeDate>
         <recordIdentifier source="DGPO">CRPT-106hrpt340</recordIdentifier>
         <recordOrigin>machine generated</recordOrigin>
         <languageOfCataloging>
              <languageTerm type="code" authority="iso639-2b">eng</languageTerm>
        </languageOfCataloging>
    </recordInfo>
    <accessCondition type="GPO scope determination">fdlp</accessCondition>
    <extension>
         <subtitle>Report to accompany H.R. 2130, including cost estimate of the Congressional Budget Office, The Committee on Commerce, to whom was referred the bill (H.R. 2130) to amend the Controlled Substances Act to add gamma hydroxybutyric acid and ketamine to the schedules of control substances, to provide for a national awareness campaign, and for other purposes, having considered the same, report favorably thereon with amendments and recommend that the bill as amended do pass. CONTENTS</subtitle>
         <docClass>HRPT</docClass>
         <accessId>CRPT-106hrpt340</accessId>
         <chamber>HOUSE</chamber>
         <congress years="1999-2000">106</congress>
         <number>340</number>
         <session>1</session>
         <isConferenceReport>false</isConferenceReport>
         <isSerialSet>true</isSerialSet>
    </extension>
    <location>
         <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/CRPT-106hrpt340</url>
    </location>
    <identifier type="preferred citation">H. Rept. 106-340</identifier>
    <titleInfo>
         <title>HILLORY J. FARIAS DATE-RAPE PREVENTION DRUG ACT OF 1999</title>
         <partName>Part 1</partName>
    </titleInfo>
    <relatedItem type="otherFormat" xlink:href="https://www.govinfo.gov/content/pkg/CRPT-106hrpt340/html/CRPT-106hrpt340-pt1.htm">
         <identifier type="FDsys Unique ID">D09002ee1ce4669d7</identifier>
    </relatedItem>
    <relatedItem type="otherFormat" xlink:href="https://www.govinfo.gov/content/pkg/CRPT-106hrpt340/pdf/CRPT-106hrpt340-pt1.pdf">
         <identifier type="FDsys Unique ID">D09002ee1ce4669d8</identifier>
    </relatedItem>
    <identifier type="uri">https://www.govinfo.gov/app/details/CRPT-106hrpt340/CRPT-106hrpt340-pt1</identifier>
    <identifier type="former granule identifier">f:hr340p1.106.txt</identifier>
    <location>
         <url displayLabel="Content Detail" access="object in context">https://www.govinfo.gov/app/details/CRPT-106hrpt340/CRPT-106hrpt340-pt1</url>
         <url access="raw object" displayLabel="PDF rendition">https://www.govinfo.gov/content/pkg/CRPT-106hrpt340/pdf/CRPT-106hrpt340-pt1.pdf</url>
         <url access="raw object" displayLabel="HTML rendition">https://www.govinfo.gov/content/pkg/CRPT-106hrpt340/html/CRPT-106hrpt340-pt1.htm</url>
    </location>
    <identifier type="preferred citation">H. Rept. 106-340,Part 1</identifier>
    <abstract>The Committee on Commerce, to whom was referred the bill (H.R. 2130) to amend the Controlled Substances Act to add gamma hydroxybutyric acid and ketamine to the schedules of control substances, to provide for a national awareness campaign, and for other purposes, having considered the same, report favorably thereon with amendments and recommend that the bill as amended do pass.</abstract>
    <extension>
         <searchTitle>HILLORY J. FARIAS DATE-RAPE PREVENTION DRUG ACT OF 1999;H. Rept. 106-340,Part 1</searchTitle>
         <legislativeHistory>Ordered to be printed</legislativeHistory>
         <granuleClass>FIRSTPART</granuleClass>
         <accessId>CRPT-106hrpt340-pt1</accessId>
         <action date="1999-09-27">Ordered to be printed</action>
         <heading>Part 1</heading>
         <session>1</session>
         <shortTitle>Hillory J. Farias Date-Rape Prevention Drug Act of 1999</shortTitle>
         <recommendation>The Committee on Commerce, to whom was referred the bill (H.R. 2130) to amend the Controlled Substances Act to add gamma hydroxybutyric acid and ketamine to the schedules of control substances, to provide for a national awareness campaign, and for other purposes, having considered the same, report favorably thereon with amendments and recommend that the bill as amended do pass.</recommendation>
         <submittedStatement>Mr. Bliley, from the Committee on Commerce, submitted the following</submittedStatement>
         <bill congress="106" context="OTHER" number="2130" type="HR"></bill>
         <bill congress="106" context="PRIMARY" number="2130" type="HR"></bill>
         <congCommittee authorityId="hsif00" chamber="H" congress="106" type="S">
                                    
              <name type="authority-standard">Committee on Commerce</name>
                                    
              <name type="authority-short">Commerce</name>
                                
        </congCommittee>
         <congMember bioGuideId="B000556" chamber="H" congress="106" party="R" role="SUBMITTEDBY" state="VA">
                                    
              <name type="parsed">Mr. Bliley</name>
                                    
              <name type="authority-fnf">Tom Bliley</name>
                                    
              <name type="authority-lnf">Bliley, Tom</name>
                                    
              <name type="authority-other">Thomas Bliley</name>
                                
        </congMember>
         <USCode title="18">
                                    
              <section number="16"></section>
                                
        </USCode>
         <USCode title="21">
                                    
              <section detail="(b)(3)" number="310"></section>
                                    
              <section number="355"></section>
                                    
              <section detail="(i)" number="355"></section>
                                    
              <section detail="et seq." number="801"></section>
                                    
              <section detail="(32)" number="802"></section>
                                    
              <section detail="(34)" number="802"></section>
                                    
              <section detail="(b)(3)" number="812"></section>
                                    
              <section detail="(c)" number="812"></section>
                                    
              <section number="813"></section>
                                    
              <section number="827"></section>
                                    
              <section number="830"></section>
                                    
              <section detail="(b)(1)(C)" number="841"></section>
                                    
              <section detail="(b)(1)(D)" number="841"></section>
                                    
              <section detail="(b)(7)" number="841"></section>
                                    
              <section detail="(b)(7)(A)" number="841"></section>
                                
        </USCode>
         <associatedBills>H.R. 2130, 106th</associatedBills>
    </extension>
    <name type="personal">
         <namePart>Tom Bliley</namePart>
         <affiliation>United States House of Representatives</affiliation>
         <role>
              <roleTerm authority="marcrelator" type="text">sponsor</roleTerm>
              <roleTerm authority="marcrelator" type="code">spn</roleTerm>
        </role>
         <description>United States Congress Member</description>
    </name>
    <name type="corporate">
         <namePart>United States</namePart>
         <namePart>Congress</namePart>
         <namePart>House of Representatives</namePart>
         <namePart>Committee on Commerce</namePart>
         <role>
              <roleTerm authority="marcrelator" type="text">associated name</roleTerm>
              <roleTerm authority="marcrelator" type="code">asn</roleTerm>
        </role>
         <description>Government Organization</description>
    </name>
    <relatedItem type="isReferencedBy">
         <titleInfo>
              <title>United States House Bill 2130 (106th Congress)</title>
        </titleInfo>
         <identifier type="Congressional Bill citation">H.R. 2130</identifier>
         <extension>
              <congress>106</congress>
              <context>OTHER</context>
        </extension>
    </relatedItem>
    <relatedItem type="isReferencedBy">
         <titleInfo>
              <title>United States House Bill 2130 (106th Congress)</title>
        </titleInfo>
         <identifier type="Congressional Bill citation">H.R. 2130</identifier>
         <extension>
              <congress>106</congress>
              <context>PRIMARY</context>
        </extension>
    </relatedItem>
    <relatedItem type="isReferencedBy">
         <titleInfo>
              <title>United States Code</title>
              <partNumber>Title 18 Section 16</partNumber>
        </titleInfo>
         <identifier type="USC citation">18 U.S.C. 16</identifier>
    </relatedItem>
    <relatedItem type="isReferencedBy">
         <titleInfo>
              <title>United States Code</title>
              <partNumber>Title 21 Section 310(b)(3)</partNumber>
              <partNumber>Title 21 Section 355</partNumber>
              <partNumber>Title 21 Section 355(i)</partNumber>
              <partNumber>Title 21 Section 801et seq.</partNumber>
              <partNumber>Title 21 Section 802(32)</partNumber>
              <partNumber>Title 21 Section 802(34)</partNumber>
              <partNumber>Title 21 Section 812(b)(3)</partNumber>
              <partNumber>Title 21 Section 812(c)</partNumber>
              <partNumber>Title 21 Section 813</partNumber>
              <partNumber>Title 21 Section 827</partNumber>
              <partNumber>Title 21 Section 830</partNumber>
              <partNumber>Title 21 Section 841(b)(1)(C)</partNumber>
              <partNumber>Title 21 Section 841(b)(1)(D)</partNumber>
              <partNumber>Title 21 Section 841(b)(7)</partNumber>
              <partNumber>Title 21 Section 841(b)(7)(A)</partNumber>
        </titleInfo>
         <identifier type="USC citation">21 U.S.C. 310(b)(3)</identifier>
         <identifier type="USC citation">21 U.S.C. 355</identifier>
         <identifier type="USC citation">21 U.S.C. 355(i)</identifier>
         <identifier type="USC citation">21 U.S.C. 801et seq.</identifier>
         <identifier type="USC citation">21 U.S.C. 802(32)</identifier>
         <identifier type="USC citation">21 U.S.C. 802(34)</identifier>
         <identifier type="USC citation">21 U.S.C. 812(b)(3)</identifier>
         <identifier type="USC citation">21 U.S.C. 812(c)</identifier>
         <identifier type="USC citation">21 U.S.C. 813</identifier>
         <identifier type="USC citation">21 U.S.C. 827</identifier>
         <identifier type="USC citation">21 U.S.C. 830</identifier>
         <identifier type="USC citation">21 U.S.C. 841(b)(1)(C)</identifier>
         <identifier type="USC citation">21 U.S.C. 841(b)(1)(D)</identifier>
         <identifier type="USC citation">21 U.S.C. 841(b)(7)</identifier>
         <identifier type="USC citation">21 U.S.C. 841(b)(7)(A)</identifier>
    </relatedItem>
</mods>